Clinical Trial: Treatment of Erectile Dysfunction (ED) in Patients Treated for Prostate Cancer


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Treatment of Erectile Dysfunction (ED) in Patients Treated for Prostate Cancer

This study is currently recruiting patients.

Sponsored by:	National Institute of Nursing Research (NINR)
Information provided by:	National Institute of Nursing Research (NINR)

Purpose

The purpose of this study is to see if there is a significant difference in erectile function between men treated with sildenafil (FDA approved drug for treatment of erectile dysfunction) versus placebo after radiation therapy (RT) plus neoadjuvant total androgen suppression (TAS) for prostate cancer and to determine if there is a significant difference in overall sexual function and satisfaction between men treated with sildenafil versus placebo.

Condition	Treatment or Intervention	Phase
Prostate Cancer	Drug: Sildenafil	Phase III

MedlinePlus related topics: Prostate Cancer

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study

Official Title: Treatment of Erectile Dysfunction in Patients Treated for Prostate Cancer

Further Study Details:

Expected Total Enrollment: 332

Study start: September 2001; Study completion: August 2004

This is a Phase III study. The study targets men with stage II and III prostate cancer recruited from the Radiation Therapy Oncology Group clinical trial (RTOG 99-10) treated with either 8 or 28 weeks of neoadjuvant TAS and RT with concurrent (8 week duration) TAS.

Eligibility

Ages Eligible for Study: 25 Years - 65 Years, Genders Eligible for Study: Male

Criteria

Men with prostate cancer in stages II-III.

Location and Contact Information

Pennsylvania
American College of Radiology, Philadelphia, Pennsylvania, 19107, United States; Recruiting

Deborah W Bruner, PhD 215-728-2967 D_WATKINS-BRUNER@FCCC.EDU

More Information

Study ID Numbers: 1-R01-NR007971-01
Record last reviewed: January 2004
Record first received: January 2, 2004
ClinicalTrials.gov Identifier: NCT00075127
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-08

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services